Anchor Investment Management LLC Raises Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Anchor Investment Management LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 4,523.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,138 shares of the medical equipment provider's stock after acquiring an additional 7,962 shares during the quarter. Anchor Investment Management LLC's holdings in Boston Scientific were worth $727,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Boston Scientific by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider's stock valued at $11,869,805,000 after purchasing an additional 1,600,062 shares during the period. Wellington Management Group LLP boosted its stake in shares of Boston Scientific by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after buying an additional 3,344,571 shares during the period. Geode Capital Management LLC grew its position in shares of Boston Scientific by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider's stock worth $2,729,371,000 after buying an additional 1,041,329 shares in the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific during the fourth quarter worth approximately $1,762,522,000. Finally, Franklin Resources Inc. raised its holdings in Boston Scientific by 5.3% in the fourth quarter. Franklin Resources Inc. now owns 16,539,488 shares of the medical equipment provider's stock valued at $1,477,307,000 after acquiring an additional 832,386 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded down $1.08 during midday trading on Monday, hitting $94.04. The stock had a trading volume of 3,004,435 shares, compared to its average volume of 6,357,740. Boston Scientific Co. has a 1 year low of $66.80 and a 1 year high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a 50 day moving average price of $99.46 and a two-hundred day moving average price of $94.48. The company has a market capitalization of $139.09 billion, a PE ratio of 75.23, a P/E/G ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the transaction, the executive vice president now owns 28,454 shares of the company's stock, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 133,183 shares of company stock valued at $13,948,476. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Barclays boosted their price target on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Truist Financial lowered their target price on shares of Boston Scientific from $120.00 to $113.00 and set a "buy" rating for the company in a research note on Friday, April 11th. Raymond James raised their price target on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Royal Bank of Canada upped their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Finally, UBS Group raised their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $110.22.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.